Evaluation of commercially available Escherichia coli J5 bacterin as protection against experimental challenge with Pasteurella multocida in rabbits

American Journal of Veterinary Research

Volumn 60, Issue 7, 1999, Pages 853-859

  Ruble, Randall P ^a   Cullor, James S ^a   Brooks, Dale L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL VACCINE; BACTERIUM ANTIBODY;

ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD; CHEMISTRY; CLASSIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; GRAM NEGATIVE INFECTION; HEMATOCRIT; IMMUNIZATION; IMMUNOLOGY; MALE; MICROBIOLOGY; PASTEURELLA MULTOCIDA; PATHOGENICITY; RABBIT;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL VACCINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; HEMATOCRIT; IMMUNIZATION; MALE; PASTEURELLA INFECTIONS; PASTEURELLA MULTOCIDA; RABBITS;

EID: 0033159625     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. De Long D, Manning PJ. Bacterial diseases. In: Manning PJ, Ringler DH, Newcomer CE, eds. The biology of the laboratory rabbit. 2nd ed. San Diego: Academic Press Inc, 1994;131-150.
2. Webster LT. The epidemiology of a rabbit respiratory infection: I: introduction. J Exp Med 1924;34:837-841.
3. Webster LT. The epidemiology of a rabbit respiratory infection: IV: susceptibility of rabbits to spontaneous snuffles. J Exp Med 1924;40:109-127.
4. Webster LT. Epidemiological studies on respiratory infections of the rabbit. Pneumonias associated with Bacterium leptisepticum. J Exp Med 1926;53:555-571.
5. Smith T. A contribution to the study of the microbe of rabbit septicemia. J Comp Med Surg 1886;8:24-37.
6. DiGiacomo RF, Garlinghouse LE, Van Hoosier GL. Natural history of infection with Pasteurella multocida in rabbits. J Am Vet Med Assoc 1983;183:1172-1175.
7. Hagen KW. Enzootic pasteurellosis in domestic rabbits: I: pathology and bacteriology. J Am Vet Med Assoc 1958;133:77-80.
8. DiGiacomo RE Transmission of Pasteurella multocida in rabbits. Lab Anim Sci 1987;37:533.
9. Flatt RE, Deyoung DW, Hogle RM. Suppurative otitis media in the rabbit: prevalence, pathology, and microbiology. Lab Anim Sci 1977;27:343-347.
10. Glass LS, Beasley JN. Infection with and antibody response to Pasteurella multotida and Bordetella bronchiseptica in immature rabbits. Lab Anim Sci 1989;39:406-410.
11. Nakagawa M, Nakayama K, Saito M, et al. Bacteriological and serological studies on Pasteurella multocida infection in rabbits. Exp Anim 1986;35:463-469.
12. Lu Y, Lai WC, Fakes SP, et al. The outer membrane of Pasteurella multocida 3:A protects rabbits against homologous challenge. Infect Immun 1991;59:4517-4523.
13. Lu Y, Pakes SP, Massey L. Hyperimmune serum from rabbits immunized with potassium thiocyanate extract of Pasteurella multocida protects against homologous challenge. J Clin Microbiol 1987;25: 2173-2180.
14. Lu Y, Pakes SP, Massey L, et al. A potassium thiocyanate extract vaccine prepared from Pasteurella multocida 3:A protects against homologous challenge. Infect Immun 1987;55:2967-2976.
15. Deeb BJ, DiGiacomo RF, Bernard BL, et al. Field trial of a live streptomycin dependent Pasteurella multocida serotype A:12 vaccine in rabbits. Lab Anim Sci 1989;39:229-233.
16. Dell A, Oates J. The enterobacterial common-antigen, a cyclic polysaccharide. Carbohydr Res 1984;133:95-104.
17. Osborn MJ. Biosynthesis and structure of the core region of the lipopolysaccharide in Salmonella typhimurium. Ann N Y Acad Sci 1965;133:375-383.
18. Gigliotti F; Shenep JL. Failure of monoclonal antibodies to core glycolipid to bind intact smooth strains of Escherichia coli. J Inject Dis 1985;151:1005-1011.
19. Chedid L, Parant M, Parant F, et al. A proposed mechanism for natural immunity to enterobacterial pathogens. J Immunol 1968;100:292-301.
20. Davis CE, Ziegler EJ, Arnold KF. Neutralization of meningococcal endotoxin by antibody to core glycolipid. J Exp Med 1978;146:1007-1017.
21. McCabe WR, Kreger BE, Johns M. Type-specific and cross-reactive antibodies in gram-negative bacteremia. N Engl J Med 1972;287:261-267.
22. McCabe WR, Bruins SC, Craven DE, et al. Cross-reactive antigens: their potential for immunization-induced immunity to gram-negative bacteria. J Infect Dis 1977;136:161-166.
23. Schmidt G, Fromme I, Mayer H. Immunochemical studies on core lipopolysaccharides of Enterobacteriaceae of different genera. Eur J Biochem 1970;14:357-366.
24. Mutharia LM, Crockford G, Bogard WC, et al. Monoclonal antibodies specific for Escherichia coli J5 lipopolysaccharide: cross-reaction with other gram-negative bacterial species. Infect Immun 1984;45:631-636.
25. Nelles MJ, Niswander CA. Mouse monoclonal antibodies reactive with J5 lipopolysaccharide exhibit extensive serological cross-reactivity with a variety of gram-negative bacteria. Infect Immun 1984;46:677-681.
26. Pollack M, Chia JKS, Koles NL, et al. Monoclonal antibodies that recognize epitopes in the core and lipid A region of lipopolysaccharides. in: Levin J, Alving CR, Mumford RS, et al, eds. Bacterial endotoxins: pathophysiological effects, clinical significance, and pharmacological control. New York: Alan R. Liss, 1988; 327-338.
27. Aydintug MK, Inzanna TJ, Letonju T, et al. Cross reactivity of monoclonal antibodies to Escherichia coli J5 with heterologous gram negative bacteria and extracted lipopolysaccharide. J Infect Dis 1989;160:846-857
28. Fenwick BW, Cullor JS, Osburn BI, et al. Mechanisms involved in protection provided by immunization against core lipopolysaccharide of Eicherichia coli J5 from lethal Haemophilus pleuropneumoniae infections in swine. Infect Immun 1986;53:298-304.
29. Pollack M, Chia JKS, Koles NL, et al. Specificity and cross reactivity of monoclonal antibodies reactive with the core and lipid A regions of bacterial lipopolysaccharide. J Infect Dis 1989;159:168-188.
30. Dunn DL, Ewald DC, Chandan N, et al. Immunotherapy of gram-negative sepsis. Arch Surg 1986;121:58-62.
31. Marks MI, Ziegler EJ, Douglas H. Induction of immunity against lethal Hemophilus influenza Type b infection by Escherichia coli core lipopolysaccharide. J Clin Invest 1982;69:742-749.
32. Tyler JW, Cullor JS, Osburn BI, et al. Relationship between serologic recognition of Escherichia coli 0111:B4 (J5) and clinical coliform mastitis. Am J Vet Res 1988;49:1950-1954.
33. Fenwick BW, Osburn BI, Cullor JS, et al. Mortality in swine herds endemically infected with Hemophilus pleuropneumoniae: effect of immunization with cross-reacting lipopolysaccharide core antigens of Escherichia coli. Am J Vet Res 1986;47:1888-1891.
34. Tyler JW, Cullor JS, Thurmond MC, et al. Humoral recognition of lipopolysaccharide core antigens of gram-negative bacteria in neonatal swine. Am J Vet Res 1989;50:126-130.
35. Dunn DL, Mach PA, Condie RM, et al. Anticore endotoxin F(ab')2 equine immunoglobulin fragments protect against lethal effects of gram-negative bacterial sepsis. Surgery 1984;96:440-446.
36. Ziegler EJ, McCutchanJA, Fierer J, et al. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 1982;307:1225-1230.
37. Stoll BJ, Pollack M, Hooper JA. Antibodies to endotoxin core determinants in normal subjects and in immune globulin for intravenous use. Serodiagn Immunother 1987;1:21-31.
38. Dunn DL, Ferguson R. Immunotherapy of gram-negative bacterial sepsis: enhanced survival in a guinea pig model by use of rabbit antiserum to Escherichia coli J5. Surgery 1982;92:212-219.
39. Al-Lebban ZS, Corbeil LB, Coles EH. Rabbit pasteurellosis: induced disease and vaccination. Am J Vet Res 1988;49:312-316.
40. Corbeil LB, Strayer DS, Skaletsky E. Immunity to pasteurellosis in compromised rabbits. Am J Vet Res 1983;44:845-850.
41. Ruble RP, Cullor JS, Brooks DL. Seroprevalence of antibodies directed towards gram-negative core antigens (GNCA) in rabbits as assessed with a J5 Escherichia coli capture antigen enzyme linked immunosorbent assay (ELISA). Am J Vet Res 1999;60:501-506.
42. Morris DD, Cullor JS, Whitlock RH, et al. Endotoxemia in neonatal calves given antiserum to a mutant Escherichia coli (J-5). Am J Vet Res 1986;47:2554-2565.
43. Douglas VL, Cullor JS, Tyler JW, et al. Rapid decay of serum IgG recognizing gram-negative cell wall core antigens in neonatal calves. Am J Vet Res 1989;50:1138-1140.
44. Dillehay DL, Paul KS, DiGiacomo RF, et al. Pathogenicity of Pasteurella multocida A:3 in Flemish giant and New Zealand white rabbits. Lab Anim 1991;25:337-341.
45. LiPuma JJ, Mortensen JE, Dasen SE, et al. Ribotype analysis of Pseudomonas cepacia from cystic fibrosis treatment centers. J Pedtat 1988;113:859-862.
46. Stull TL, LiPuma JJ, Edlind TD. A broad-spectrum probe for molecular epidemiology of bacteria: ribosomal RNA. J Infect Dis 1988;157:280-286.
47. Snipes KP, Hirsh DC, Kasten RW, et al. Differentiation of field isolates of Pasteurella multocida serotype 3,4 from live vaccine strain by genotypic characterization. Avian Dis 1990;34:419-423.
48. Snipes KP, Hirsh DC, Kasten RW, et al. Use of an rRNA probe and restriction endonuclease analysis to fingerprint Posteurella multocida from turkeys and wildlife. J Clin Micro 1989;27:1847-1853.
49. Bortolotti A, Castelli D, Bonati M. Hematology and serum chemistry values of adult, pregnant and new born New Zealand White Rabbits (Oryctolagus cuniculus). Lab Anim Sci 1989;39:437-439.
50. Toth LA, Krueger JM. Hematologic effects of exposure to three infective agents in rabbits. J Am Vet Med Assoc 1989;195:981-986.
51. Glorioso JC, Jones GW, Rush HG. Adhesion of type A Pasteurella multocida to rabbit pharyngeal cells and its possible role in rabbit respiratory tract infections. Inject Immun 1982,35: 1103-1109.
52. Al-Lebban ZS, Kruckenberg S, Coles EH. Rabbit pasteurellosis: respiratory and renal pathology of control and immunized rabbits after challenge with Pasteurella multocida. Histol Histopathol 1989;4:77-84.
53. Tyler JW, Spears H, Nelson R. Antibiotic homology of endotoxin with coliform mastitis vaccine strain Escherichia coli 0111:B4(J5). J Dairy Sci 1992;75:1821-1825.
54. Tyler JW, Cullor JS, Douglas VL, et al. Preferential decay of passively acquired immunoglobulins recognizing shared gram-negative core antigens in neonatal swine. Am J Vet Res 1989;50:480-482.
55. Bockenstedt LK, Barthold S, Deponte K, et al. Borrelia burgdorferi infection and immunity in mice deficient in the fifth component of complement. Inject Immun 1993;61:2104-2107.
56. Bockenstedt LK, Fikrig E, Barthold S, et al. Inability of truncated recombinant OspA proteins to elicit protective immunity to Borrelia burgdorferi in mice. J Immunol 1993;151.900-906
57. Lee MD, Wooley RE, Glisson JR. Invasion of epithelial cell monolayers by turkey strains of Posteurella multocida. Avian Dis 1994;38:72-77.
58. Rabier MJ, Tyler NK, Guse NJ, et al. Pasteurella multocida enters polarized epithelial cells by interacting with host F-actin. Vet Microbiol 1997;54:343-355.
59. Glorioso JC, Jones GW, Rush HG, et al. Adhesion of Type A Pasteurella multocida to rabbit pharyngeal cells and its possible role in rabbit respiratory tract infections. Infect Immun 1982;35:1103-1109.
60. Walker RL. New strategies for using mucosal vaccination to achieve more effective immunization. Vaccine 1994;12:387-400.
61. Berstad AKH, Holst J, Mogster B, et al. A nasal whole-cell pertussis vaccine can induce strong systemic and mucosal antibody responses which are not enhanced by cholera toxin. Vaccine 1997;15: 1473-1477.
62. Suckow MA, Bowersock TL, Nielsen K, et al. Enhancement of respiratory immunity to Pasteurella multocida by cholera toxin in rabbits. Lab Anim 1996;30:120-126.
63. Suckow MA, Bowersock TL, Park H, et al. Oral immunization of rabbits against Pasteurella multocida with an alginate microsphere delivery system. J Biomater Sci Polym Ed 1996;8:131-139.
64. Hanly WC, Bennett BT, Artwohl JE. Overview of adjuvants. In: Smith PS, Jensen D, Allen T, et al, eds. Information resources for adjuvants and antibody production comparisons and alternative technologies. Washington, DC: United States Department of Agriculture, 1997;1-6.
65. Jennings VM. Review of selected adjuvants used in antibody production. Instit Lab Anim Res J 1995;37:119-125
66. Eldridge JH, Stass JK, Meulbroek JA, et al. Biodegradable microspheres as a vaccine delivery system. Molec Immun 1991;28: 287-297.
67. Hioe CE, Qiu H, Chend P, et al. Comparison of adjuvant formulations for cytotoxic T cell induction using synthetic peptides. Vaccine 1996;14:412-418.
68. Allison AC, Byars NE. An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell mediated immunity. J Immunol Meth 1986,95:157-68.
69. Bomford R. The comparative selectivity of adjuvants for humoral and cell-mediated immunity. II: effect on delayed-type hypersensitivity in the mouse and guinea pig, and cell mediated immunity to tumor antigens in the mouse of Freund's incomplete and complete adjuvants, hydrogel, Corynebacterium parvum, Bordetella pertussis, muramyl dipeptide and saponin. Clin Exp Immunol 1980:39:435-441.
70. Gupta RK, Griffin P, Chan A, et al. The role of adjuvants and delivery systems in modulation of immune response to vaccine. In: Chohen S, Shafferman A, eds. Novel strategies in design and production of vaccines. New York: A Plenum Press, 1996;105-113.
71. Okerman L, Spanoghe L. Protective effects of inactivated Pasteurella vaccines in specific pathogen free rabbits. Comp Immunol Microbiol Infect Dis 1981;2:223-228.
72. Okerman L, Devriese LA. Failure of oil adjuvants to enhance immunity induced in mice by an inactivated rabbit Pasteurella multocida vaccine. Vaccine 1987;5:315-318.
73. Nakamura T, Hoshi S, Nagasqwa Y, et al. The effect of inoculation route on protection by killed vaccines in chickens. Avian Dis 1995;39:507-513.